Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1989 Aug;151(2):161–167.

Myelodysplastic syndromes.

D C Doll, A F List
PMCID: PMC1026906  PMID: 2672599

Abstract

The myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by dysplastic and ineffective hematopoiesis and a varying risk of transformation to acute leukemia. Although the natural history of these syndromes is variable, several factors appear to be of prognostic importance, including the French-American-British classification, the karyotype, in vitro colony formation, and others. The pathogenesis of the myelodysplastic syndrome is not known, but recent evidence suggests that alterations of cellular oncogenes may be a causative factor. There is no standard therapy for myelodysplasia, and thus novel approaches to patient management are warranted.

Full text

PDF
161

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum F. R., Storb R., Ramberg R. E., Shulman H. M., Buckner C. D., Clift R. A., Deeg H. J., Fefer A., Sanders J., Stewart P. Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med. 1984 May;100(5):689–693. doi: 10.7326/0003-4819-100-5-689. [DOI] [PubMed] [Google Scholar]
  2. Armitage J. O., Dick F. R., Needleman S. W., Burns C. P. Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):601–605. [PubMed] [Google Scholar]
  3. Ayanlar-Batuman O., Shevitz J., Traub U. C., Murphy S., Sajewski D. Lymphocyte interleukin 2 production and responsiveness are altered in patients with primary myelodysplastic syndrome. Blood. 1987 Aug;70(2):494–500. [PubMed] [Google Scholar]
  4. Bagby G. C., Jr, Gabourel J. D., Linman J. W. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques. Ann Intern Med. 1980 Jan;92(1):55–58. doi: 10.7326/0003-4819-92-1-55. [DOI] [PubMed] [Google Scholar]
  5. Barton J. C., Conrad M. E., Parmley R. T. Acute lymphoblastic leukemia in idiopathic refractory sideroblastic anemia: evidence for a common lymphoid and myeloid progenitor cell. Am J Hematol. 1980;9(1):109–115. doi: 10.1002/ajh.2830090111. [DOI] [PubMed] [Google Scholar]
  6. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189–199. [PubMed] [Google Scholar]
  7. Blok W. L., Lowenberg B., Sizoo W. Disappearance of trisomy 8 after alpha-2 interferon in a patient with myelodysplastic syndrome. N Engl J Med. 1988 Mar 24;318(12):787–788. [PubMed] [Google Scholar]
  8. Boehme W. M., Piira T. A., Kurnick J. E., Bethlenfalvay N. C. Acquired hemoglobin H in refractor sideroblastic anemia. A preleukemic marker. Arch Intern Med. 1978 Apr;138(4):603–606. [PubMed] [Google Scholar]
  9. Boogaerts M. A., Nelissen V., Roelant C., Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol. 1983 Oct;55(2):217–227. doi: 10.1111/j.1365-2141.1983.tb01241.x. [DOI] [PubMed] [Google Scholar]
  10. Breitman T. R., Selonick S. E., Collins S. J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980 May;77(5):2936–2940. doi: 10.1073/pnas.77.5.2936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bynoe A. G., Scott C. S., Ford P., Roberts B. E. Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol. 1983 May;54(1):97–102. doi: 10.1111/j.1365-2141.1983.tb02071.x. [DOI] [PubMed] [Google Scholar]
  12. Cheson B. D., Jasperse D. M., Simon R., Friedman M. A. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol. 1986 Dec;4(12):1857–1864. doi: 10.1200/JCO.1986.4.12.1857. [DOI] [PubMed] [Google Scholar]
  13. Cines D. B., Cassileth P. A., Kiss J. E. Danazol therapy in myelodysplasia. Ann Intern Med. 1985 Jul;103(1):58–60. doi: 10.7326/0003-4819-103-1-58. [DOI] [PubMed] [Google Scholar]
  14. Clark R. E., Ismail S. A., Jacobs A., Payne H., Smith S. A. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol. 1987 May;66(1):77–83. doi: 10.1111/j.1365-2141.1987.tb06893.x. [DOI] [PubMed] [Google Scholar]
  15. Clark R. E., Jacobs A., Lush C. J., Smith S. A. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet. 1987 Apr 4;1(8536):763–765. doi: 10.1016/s0140-6736(87)92796-6. [DOI] [PubMed] [Google Scholar]
  16. Clark R., Peters S., Hoy T., Smith S., Whittaker K., Jacobs A. Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes. N Engl J Med. 1986 Jun 5;314(23):1472–1475. doi: 10.1056/NEJM198606053142302. [DOI] [PubMed] [Google Scholar]
  17. Coiffier B., Adeleine P., Viala J. J., Bryon P. A., Fière D., Gentilhomme O., Vuvan H. Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients. Cancer. 1983 Jul 1;52(1):83–90. doi: 10.1002/1097-0142(19830701)52:1<83::aid-cncr2820520117>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  18. Copplestone J. A., Mufti G. J., Hamblin T. J., Oscier D. G. Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy. Br J Haematol. 1986 May;63(1):149–159. doi: 10.1111/j.1365-2141.1986.tb07505.x. [DOI] [PubMed] [Google Scholar]
  19. Desforges J. F. Cytarabine: low-dose, high-dose, no dose? N Engl J Med. 1983 Dec 29;309(26):1637–1639. doi: 10.1056/NEJM198312293092608. [DOI] [PubMed] [Google Scholar]
  20. Deuel T. F., Huang J. S. Roles of growth factor activities in oncogenesis. Blood. 1984 Nov;64(5):951–958. [PubMed] [Google Scholar]
  21. Doll D. C., Grogan T. M., Greenberg B. R. Chronic myelomonocytic leukemia terminating as malignant histiocytosis. Hematol Pathol. 1987;1(3):183–189. [PubMed] [Google Scholar]
  22. Doll D. C., Ringenberg Q. S., Yarbro J. W. Danazol therapy in acquired idiopathic sideroblastic anemia. Acta Haematol. 1987;77(3):170–171. doi: 10.1159/000205984. [DOI] [PubMed] [Google Scholar]
  23. Doll D. C., Taylor H. M., Yesus Y. W., Caldwell C. W., Anderson S., Madsen R., Ringenberg Q. S., Yarbro J. W. Myelodysplastic syndrome: prospective evaluation of fifty-one patients using the Dutcher scoring system. Acta Haematol. 1989;81(2):86–90. doi: 10.1159/000205532. [DOI] [PubMed] [Google Scholar]
  24. Donahue R. E., Wang E. A., Stone D. K., Kamen R., Wong G. G., Sehgal P. K., Nathan D. G., Clark S. C. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. 1986 Jun 26-Jul 2Nature. 321(6073):872–875. doi: 10.1038/321872a0. [DOI] [PubMed] [Google Scholar]
  25. Eridani S., Chan L. C., Halil O., Pearson T. C. Acute biphenotypic leukaemia (myeloid and null-ALL type) supervening in a myelodysplastic syndrome. Br J Haematol. 1985 Nov;61(3):525–529. doi: 10.1111/j.1365-2141.1985.tb02857.x. [DOI] [PubMed] [Google Scholar]
  26. Foucar K., Langdon R. M., 2nd, Armitage J. O., Olson D. B., Carroll T. J., Jr Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer. 1985 Aug 1;56(3):553–561. doi: 10.1002/1097-0142(19850801)56:3<553::aid-cncr2820560323>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  27. Gold E. J., Conjalka M., Pelus L. M., Jhanwar S. C., Broxmeyer H., Middleton A. B., Clarkson B. D., Moore M. A. Marrow cytogenetic and cell-culture analyses of the myelodysplastic syndromes: insights to pathophysiology and prognosis. J Clin Oncol. 1983 Oct;1(10):627–634. doi: 10.1200/JCO.1983.1.10.627. [DOI] [PubMed] [Google Scholar]
  28. Gold E. J., Mertelsmann R. H., Itri L. M., Gee T., Arlin Z., Kempin S., Clarkson B., Moore M. A. Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep. 1983 Nov;67(11):981–986. [PubMed] [Google Scholar]
  29. Greenberg B. R., Durie B. G., Barnett T. C., Meyskens F. L., Jr Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome. Cancer Treat Rep. 1985 Dec;69(12):1369–1374. [PubMed] [Google Scholar]
  30. Greenberg P. L. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders. Clin Haematol. 1986 Nov;15(4):973–993. [PubMed] [Google Scholar]
  31. Greenberg P. L. The smoldering myeloid leukemic states: clinical and biologic features. Blood. 1983 Jun;61(6):1035–1044. [PubMed] [Google Scholar]
  32. Griffin J. D., Spriggs D., Wisch J. S., Kufe D. W. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol. 1985 Jul;3(7):982–991. doi: 10.1200/JCO.1985.3.7.982. [DOI] [PubMed] [Google Scholar]
  33. Hauptmann G., Sondag D., Lang J. M., Oberling F. "False positive" acidified serum test in a preleukemic dyserythropoiesis. Acta Haematol. 1978;59(2):73–79. doi: 10.1159/000207748. [DOI] [PubMed] [Google Scholar]
  34. Hemmi H., Breitman T. R. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood. 1987 Feb;69(2):501–507. [PubMed] [Google Scholar]
  35. Hirai H., Okada M., Mizoguchi H., Mano H., Kobayashi Y., Nishida J., Takaku F. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood. 1988 Jan;71(1):256–258. [PubMed] [Google Scholar]
  36. Jacobs R. H., Cornbleet M. A., Vardiman J. W., Larson R. A., Le Beau M. M., Rowley J. D. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. 1986 Jun;67(6):1765–1772. [PubMed] [Google Scholar]
  37. Juneja S. K., Imbert M., Jouault H., Scoazec J. Y., Sigaux F., Sultan C. Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. J Clin Pathol. 1983 Oct;36(10):1129–1135. doi: 10.1136/jcp.36.10.1129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kere J., Ruutu T., de la Chapelle A. Monosomy 7 in granulocytes and monocytes in myelodysplastic syndrome. N Engl J Med. 1987 Feb 26;316(9):499–503. doi: 10.1056/NEJM198702263160902. [DOI] [PubMed] [Google Scholar]
  39. Knapp R. H., Dewald G. W., Pierre R. V. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc. 1985 Aug;60(8):507–516. doi: 10.1016/s0025-6196(12)60566-7. [DOI] [PubMed] [Google Scholar]
  40. Koeffler H. P., Golde D. W. Human preleukemia. Ann Intern Med. 1980 Aug;93(2):347–353. doi: 10.7326/0003-4819-93-2-347. [DOI] [PubMed] [Google Scholar]
  41. Koeffler H. P., Heitjan D., Mertelsmann R., Kolitz J. E., Schulman P., Itri L., Gunter P., Besa E. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood. 1988 Mar;71(3):703–708. [PubMed] [Google Scholar]
  42. Koeffler H. P., Hirji K., Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep. 1985 Dec;69(12):1399–1407. [PubMed] [Google Scholar]
  43. Kuriyama K., Tomonaga M., Matsuo T., Ginnai I., Ichimaru M. Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol. 1986 Aug;63(4):665–669. doi: 10.1111/j.1365-2141.1986.tb07550.x. [DOI] [PubMed] [Google Scholar]
  44. Land H., Parada L. F., Weinberg R. A. Cellular oncogenes and multistep carcinogenesis. Science. 1983 Nov 18;222(4625):771–778. doi: 10.1126/science.6356358. [DOI] [PubMed] [Google Scholar]
  45. Land H., Parada L. F., Weinberg R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983 Aug 18;304(5927):596–602. doi: 10.1038/304596a0. [DOI] [PubMed] [Google Scholar]
  46. Levine E. G., Bloomfield C. D. Secondary myelodysplastic syndromes and leukaemias. Clin Haematol. 1986 Nov;15(4):1037–1080. [PubMed] [Google Scholar]
  47. Levine M. N., Kuhns W. K., Bolk T. A., Beyer T. A., Rosse W. F. Acquired alteration in the expression of blood groups in a patient with sideroblastic anemia and chronic renal failure. Transfusion. 1984 Jan-Feb;24(1):8–12. doi: 10.1046/j.1537-2995.1984.24184122568.x. [DOI] [PubMed] [Google Scholar]
  48. Mason D. Y., Emerson P. M. Primary acquired sideroblastic anaemia: response to treatment with pyridoxal-5-phosphate. Br Med J. 1973 Feb 17;1(5850):389–390. doi: 10.1136/bmj.1.5850.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. May S. J., Smith S. A., Jacobs A., Williams A., Bailey-Wood R. The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification. Br J Haematol. 1985 Feb;59(2):311–319. doi: 10.1111/j.1365-2141.1985.tb02996.x. [DOI] [PubMed] [Google Scholar]
  50. McKusick V. A. The human gene map 1 December 1984. Clin Genet. 1985 Feb;27(2):207–239. doi: 10.1111/j.1399-0004.1985.tb00214.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood. 1986 Feb;67(2):257–267. [PubMed] [Google Scholar]
  52. Meyskens F. L., Jr, Fuller B. B. Characterization of the effects of different retinoids on the growth and differentiation of a human melanoma cell line and selected subclones. Cancer Res. 1980 Jul;40(7):2194–2196. [PubMed] [Google Scholar]
  53. Mufti G. J., Figes A., Hamblin T. J., Oscier D. G., Copplestone J. A. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol. 1986 May;63(1):143–147. doi: 10.1111/j.1365-2141.1986.tb07504.x. [DOI] [PubMed] [Google Scholar]
  54. Mufti G. J., Oscier D. G., Hamblin T. J., Bell A. J. Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. N Engl J Med. 1983 Dec 29;309(26):1653–1654. doi: 10.1056/NEJM198312293092618. [DOI] [PubMed] [Google Scholar]
  55. Mufti G. J., Stevens J. R., Oscier D. G., Hamblin T. J., Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol. 1985 Mar;59(3):425–433. doi: 10.1111/j.1365-2141.1985.tb07329.x. [DOI] [PubMed] [Google Scholar]
  56. Najean Y., Pecking A. Refractory anaemia with excess of myeloblasts in the bone marrow: a clinical trial of androgens in 90 patients. Br J Haematol. 1977 Sep;37(1):25–33. [PubMed] [Google Scholar]
  57. Nowell P. C. Cytogenetics of preleukemia. Cancer Genet Cytogenet. 1982 Mar;5(3):265–278. doi: 10.1016/0165-4608(82)90034-6. [DOI] [PubMed] [Google Scholar]
  58. Picozzi V. J., Jr, Swanson G. F., Morgan R., Hecht F., Greenberg P. L. 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol. 1986 Apr;4(4):589–595. doi: 10.1200/JCO.1986.4.4.589. [DOI] [PubMed] [Google Scholar]
  59. Prchal J. T., Throckmorton D. W., Carroll A. J., 3rd, Fuson E. W., Gams R. A., Prchal J. F. A common progenitor for human myeloid and lymphoid cells. Nature. 1978 Aug 10;274(5671):590–591. doi: 10.1038/274590a0. [DOI] [PubMed] [Google Scholar]
  60. Raskind W. H., Tirumali N., Jacobson R., Singer J., Fialkow P. J. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood. 1984 Jun;63(6):1318–1323. [PubMed] [Google Scholar]
  61. Russell N. H., Keenan J. P., Bellingham A. J. Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol. 1979 Mar;41(3):417–425. doi: 10.1111/j.1365-2141.1979.tb05876.x. [DOI] [PubMed] [Google Scholar]
  62. Ruutu P., Ruutu T., Repo H., Vuopio P., Timonen T., Kosunen T. U., de la Chapelle A. Defective neutrophil migration in monosomy-7. Blood. 1981 Oct;58(4):739–745. [PubMed] [Google Scholar]
  63. Ruutu T., Volin L., Tenhunen R. Haem arginate as a treatment for myelodysplastic syndromes. Br J Haematol. 1987 Apr;65(4):425–428. doi: 10.1111/j.1365-2141.1987.tb04144.x. [DOI] [PubMed] [Google Scholar]
  64. Scott C. S., Cahill A., Bynoe A. G., Ainley M. J., Hough D., Roberts B. E. Esterase cytochemistry in primary myelodysplastic syndromes and megaloblastic anaemias: demonstration of abnormal staining patterns associated with dysmyelopoiesis. Br J Haematol. 1983 Nov;55(3):411–418. doi: 10.1111/j.1365-2141.1983.tb02155.x. [DOI] [PubMed] [Google Scholar]
  65. Solal-Celigny P., Desaint B., Herrera A., Chastang C., Amar M., Vroclans M., Brousse N., Mancilla F., Renoux M., Bernard J. F. Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood. 1984 Mar;63(3):634–638. [PubMed] [Google Scholar]
  66. Souza L. M., Boone T. C., Gabrilove J., Lai P. H., Zsebo K. M., Murdock D. C., Chazin V. R., Bruszewski J., Lu H., Chen K. K. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986 Apr 4;232(4746):61–65. doi: 10.1126/science.2420009. [DOI] [PubMed] [Google Scholar]
  67. Sporn M. B., Roberts A. B. Autocrine growth factors and cancer. 1985 Feb 28-Mar 6Nature. 313(6005):745–747. doi: 10.1038/313745a0. [DOI] [PubMed] [Google Scholar]
  68. Tobler A., Munker R., Heitjan D., Koeffler H. P. In vitro interaction of recombinant tumor necrosis factor alpha and all-trans-retinoic acid with normal and leukemic hematopoietic cells. Blood. 1987 Dec;70(6):1940–1946. [PubMed] [Google Scholar]
  69. Tricot G. J., Lauer R. C., Appelbaum F. R., Jansen J., Hoffman R. Management of the myelodysplastic syndromes. Semin Oncol. 1987 Dec;14(4):444–453. [PubMed] [Google Scholar]
  70. Tricot G., Boogaerts M. A., De Wolf-Peeters C., Van den Berghe H., Verwilghen R. L. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol. 1985 Apr;59(4):659–670. doi: 10.1111/j.1365-2141.1985.tb07361.x. [DOI] [PubMed] [Google Scholar]
  71. Tricot G., Boogaerts M. A. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol. 1986 Jul;63(3):477–483. doi: 10.1111/j.1365-2141.1986.tb07524.x. [DOI] [PubMed] [Google Scholar]
  72. Tricot G., De Bock R., Dekker A. W., Boogaerts M. A., Peetermans M., Punt K., Verwilghen R. L. Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes. Br J Haematol. 1984 Oct;58(2):231–240. doi: 10.1111/j.1365-2141.1984.tb06081.x. [DOI] [PubMed] [Google Scholar]
  73. Tricot G., De Wolf-Peeters C., Hendrickx B., Verwilghen R. L. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol. 1984 Jul;57(3):423–430. doi: 10.1111/j.1365-2141.1984.tb02916.x. [DOI] [PubMed] [Google Scholar]
  74. Tricot G., De Wolf-Peeters C., Vlietinck R., Verwilghen R. L. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol. 1984 Oct;58(2):217–225. doi: 10.1111/j.1365-2141.1984.tb06079.x. [DOI] [PubMed] [Google Scholar]
  75. Tricot G., Mecucci C., Van den Berghe H. Evolution of the myelodysplastic syndromes. Br J Haematol. 1986 Aug;63(4):609–614. doi: 10.1111/j.1365-2141.1986.tb07544.x. [DOI] [PubMed] [Google Scholar]
  76. Tricot G., Vlietinck R., Boogaerts M. A., Hendrickx B., De Wolf-Peeters C., Van den Berghe H., Verwilghen R. L. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol. 1985 May;60(1):19–32. doi: 10.1111/j.1365-2141.1985.tb07381.x. [DOI] [PubMed] [Google Scholar]
  77. Trinchieri G., Rosen M., Perussia B. Retinoic acid cooperates with tumor necrosis factor and immune interferon in inducing differentiation and growth inhibition of the human promyelocytic leukemic cell line HL-60. Blood. 1987 Apr;69(4):1218–1224. [PubMed] [Google Scholar]
  78. Tulliez M., Testa U., Rochant H., Henri A., Vainchenker W., Touboul J., Breton-Gorius J., Dreyfus B. Reticulocytosis, hypochromia, and microcytosis: an unusual presentation of the preleukemic syndrome. Blood. 1982 Feb;59(2):293–299. [PubMed] [Google Scholar]
  79. Vadhan-Raj S., Keating M., LeMaistre A., Hittelman W. N., McCredie K., Trujillo J. M., Broxmeyer H. E., Henney C., Gutterman J. U. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987 Dec 17;317(25):1545–1552. doi: 10.1056/NEJM198712173172501. [DOI] [PubMed] [Google Scholar]
  80. Valentine W. N., Konrad P. N., Paglia D. E. Dyserythropoiesis, refractory anemia, and "preleukemia:" metabolic features of the erythrocytes. Blood. 1973 Jun;41(6):857–875. [PubMed] [Google Scholar]
  81. Vallespi T., Torrabadella M., Julia A., Irriguible D., Jaen A., Acebedo G., Triginer J. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol. 1985 Sep;61(1):83–92. doi: 10.1111/j.1365-2141.1985.tb04063.x. [DOI] [PubMed] [Google Scholar]
  82. Van den Berghe H., Cassiman J. J., David G., Fryns J. P., Michaux J. L., Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974 Oct 4;251(5474):437–438. doi: 10.1038/251437a0. [DOI] [PubMed] [Google Scholar]
  83. Vandermolen L., Rice L., Rose M. A., Lynch E. C. Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors. Arch Intern Med. 1988 Mar;148(3):653–656. [PubMed] [Google Scholar]
  84. Varela B. L., Chuang C., Woll J. E., Bennett J. M. Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system. Hematol Oncol. 1985 Jan-Mar;3(1):55–63. doi: 10.1002/hon.2900030108. [DOI] [PubMed] [Google Scholar]
  85. Weinberg J. B., Larrick J. W. Receptor-mediated monocytoid differentiation of human promyelocytic cells by tumor necrosis factor: synergistic actions with interferon-gamma and 1,25-dihydroxyvitamin D3. Blood. 1987 Oct;70(4):994–1002. [PubMed] [Google Scholar]
  86. Weisdorf D. J., Oken M. M., Johnson G. J., Rydell R. E. Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia. Br J Haematol. 1983 Dec;55(4):691–700. doi: 10.1111/j.1365-2141.1983.tb02852.x. [DOI] [PubMed] [Google Scholar]
  87. Whang-Peng J., Young R. C., Lee E. C., Longo D. L., Schechter G. P., DeVita V. T., Jr Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood. 1988 Feb;71(2):403–414. [PubMed] [Google Scholar]
  88. Winter J. N., Variakojis D., Gaynor E. R., Larson R. A., Miller K. B. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer. 1985 Aug 1;56(3):443–449. doi: 10.1002/1097-0142(19850801)56:3<443::aid-cncr2820560305>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  89. Wong G. G., Witek J. S., Temple P. A., Wilkens K. M., Leary A. C., Luxenberg D. P., Jones S. S., Brown E. L., Kay R. M., Orr E. C. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science. 1985 May 17;228(4701):810–815. doi: 10.1126/science.3923623. [DOI] [PubMed] [Google Scholar]
  90. Yunis J. J., Lobell M., Arnesen M. A., Oken M. M., Mayer M. G., Rydell R. E., Brunning R. D. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol. 1988 Feb;68(2):189–194. doi: 10.1111/j.1365-2141.1988.tb06188.x. [DOI] [PubMed] [Google Scholar]
  91. Yunis J. J., Rydell R. E., Oken M. M., Arnesen M. A., Mayer M. G., Lobell M. Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood. 1986 Jun;67(6):1721–1730. [PubMed] [Google Scholar]
  92. Zuckerman S. H., Surprenant Y. M., Tang J. Synergistic effect of granulocyte-macrophage colony-stimulating factor and 1,25-dihydroxyvitamin D3 on the differentiation of the human monocytic cell line U937. Blood. 1988 Mar;71(3):619–624. [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES